Novartis AG
NVS · NYSE
NVS · NYSE
The supplied consensus is Hold across 11 analysts, with a mean price target of $151; the low and high targets are unavailable, so target clustering and the width of the range cannot be assessed. The evidence does not identify individual analysts or their targets, so the most and least bullish analysts cannot be named. The only explicit recent rating revision is Zacks' upgrade to Rank #2 (Buy), which it attributes to improving earnings prospects; no dated sell-side target revisions are supplied. The substantive tension is between growth in key medicines and a raised core operating income outlook on one side, and a revenue miss, sharp reported profit declines and generic competition on the other.
